Pulmonx Co. (NASDAQ:LUNG) Receives $13.36 Consensus PT from Analysts

Shares of Pulmonx Co. (NASDAQ:LUNG - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $13.36.

LUNG has been the subject of a number of analyst reports. Morgan Stanley assumed coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued an "equal weight" rating for the company. Wells Fargo & Company cut their price target on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Jefferies Financial Group started coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a "buy" rating for the company. Citigroup began coverage on Pulmonx in a report on Monday, March 10th. They set a "buy" rating on the stock. Finally, D. Boral Capital started coverage on Pulmonx in a research note on Monday, March 10th. They set a "buy" rating and a $17.00 price target for the company.

Pulmonx Stock Down 1.3 %

Shares of NASDAQ:LUNG traded down $0.09 during midday trading on Friday, hitting $6.73. 310,682 shares of the stock were exchanged, compared to its average volume of 329,391. The company has a market capitalization of $267.83 million, a PE ratio of -4.67 and a beta of 0.50. Pulmonx has a 52-week low of $5.46 and a 52-week high of $10.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The business's fifty day simple moving average is $7.18 and its two-hundred day simple moving average is $6.94.

Remove Ads

Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.12. The company had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. As a group, research analysts predict that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Insider Transactions at Pulmonx

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total value of $157,000.00. Following the completion of the sale, the director now directly owns 991,974 shares of the company's stock, valued at $7,786,995.90. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Geoffrey Beran Rose sold 5,779 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now owns 285,278 shares in the company, valued at approximately $2,034,032.14. The trade was a 1.99 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 147,986 shares of company stock worth $1,143,673. Company insiders own 5.70% of the company's stock.

Institutional Investors Weigh In On Pulmonx

Several hedge funds have recently made changes to their positions in LUNG. Mackenzie Financial Corp acquired a new position in Pulmonx in the 4th quarter valued at approximately $372,000. ProShare Advisors LLC bought a new stake in shares of Pulmonx during the fourth quarter valued at approximately $72,000. Millennium Management LLC raised its stake in shares of Pulmonx by 26.6% in the fourth quarter. Millennium Management LLC now owns 183,069 shares of the company's stock valued at $1,243,000 after purchasing an additional 38,425 shares in the last quarter. Graham Capital Management L.P. lifted its position in Pulmonx by 73.3% in the fourth quarter. Graham Capital Management L.P. now owns 18,071 shares of the company's stock worth $123,000 after purchasing an additional 7,641 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its stake in Pulmonx by 8.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 392,836 shares of the company's stock worth $2,667,000 after buying an additional 32,049 shares in the last quarter. Institutional investors own 91.04% of the company's stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.